Skip to main content

Table 2 Precision in the estimated grade 3–4 treatment-emergent adverse event rate with a total cohort size of 93 patients

From: Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

AE rate

Exact 95% confidence interval

Probability of seeing at least one event

1%

(0.0%, 5.8%)

0.607

2%

(0.7%, 9.1%)

0.847

3%

(1.2%, 10.6%)

0.941

4%

(1.2%, 10.6%)

0.978

5%

(1.8%, 12.1%)

0.992